🔎 Trials Near Me

Utama › Kanser Paru-paru Bukan Sel Kecil › Georgia › Athens

Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Athens, GA

17 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Athens (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Mengambil pesertaFasa 3
  • University Cancer & Blood Center, LLC, Athens
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07361510

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Mengambil pesertaFasa 3
  • University Cancer and Blood Center, Athens
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT06881784

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Mengambil pesertaFasa 2
  • University Cancer & Blood Center, LLC, Athens
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07489066

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Mengambil pesertaFasa 3
  • University Cancer & Blood Center, LLC, Athens
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06890598

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Mengambil pesertaFasa 2/3
  • University Cancer & Blood Center (UCBC) - Athens, Athens
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04613596

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Mengambil pesertaFasa 3
  • University Cancer & Blood Center, LLC, Athens
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06119581

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Mengambil pesertaFasa 1
  • University Cancer & Blood Center, Athens
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Jul 2026 · NCT06150664

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2
  • University Cancer and Blood Center LLC, Athens
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Jun 2026 · NCT05642572

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Mengambil pesertaFasa 1/2
  • University Cancer and Blood Center, Athens
Umur 12 ke atas · Semua jantina · Dikemas kini 27 Mei 2026 · NCT03093116

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Mengambil pesertaFasa 2
  • University Cancer and Blood Center LLC, Athens
18 Minutes · Semua jantina · Dikemas kini 5 Mei 2026 · NCT06031688

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Mengambil pesertaFasa 2
  • University Cancer & Blood Center, Athens
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Apr 2026 · NCT05168566

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Mengambil pesertaFasa 2
  • University Cancer & Blood Center (UCBC) - Athens, Athens
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Apr 2026 · NCT06010329

Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain

Kajian lain di Athens

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.